Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation

Victor I. Machicao, Murli Krishna, Hugo Bonatti, Bashar A. Aqel, Justin H Nguyen, Stephen D. Weigand, Barry G. Rosser, Christopher Hughes, Rolland Dickson

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The natural history of allograft steatosis in hepatitis C (HCV)-infected patients after liver transplantation (LT) is poorly understood. The aim of our study was to determine the relationship of allograft steatosis to HCV recurrence after LT. All patients undergoing LT at our center from March 1998 to December 2001 were included in the study. Explanted liver tissue and liver biopsies performed at 1 week, 4 months, and 12 months were scored for degree of allograft steatosis (0-4), fibrosis (0-6), and modified histological activity index (0-18). One hundred sixty-seven HCV and 235 non-HCV-infected patients (control group) underwent LT. Of these patients, 122 HCV and 154 non-HCV patients had a viable graft at 1 year and were analyzed. Allograft steatosis was present in 40% of HCV patients at 4 months and 36% at 1 year. The incidence of allograft steatosis after LT was similar in HCV-infected and non-HCV-infected patients (P not significant). Age of the donor (P = .041), or higher recipient body mass index (BMI) at the time of LT (P = .015) or at 12 months after LT (P = .041) predicted a higher degree of allograft steatosis at 12 months in the HCV group. Degree of allograft steatosis was not associated with higher fibrosis or necroinflammatory score. In conclusion, there is a similar high incidence of allograft steatosis in HCV and non-HCV-infected patients after LT. A high BMI of the HCV-infected recipient is the best predictor for high degree of allograft steatosis after LT. Allograft steatosis does not predict the severity of HCV recurrence in the first 12 months after LT.

Original languageEnglish (US)
Pages (from-to)599-606
Number of pages8
JournalLiver Transplantation
Volume10
Issue number5
DOIs
StatePublished - May 2004

Fingerprint

Hepatitis C
Liver Transplantation
Allografts
Recurrence
Fatty Liver
Body Mass Index
Fibrosis
Liver
Incidence
Natural History
Tissue Donors
Transplants
Biopsy
Control Groups

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation. / Machicao, Victor I.; Krishna, Murli; Bonatti, Hugo; Aqel, Bashar A.; Nguyen, Justin H; Weigand, Stephen D.; Rosser, Barry G.; Hughes, Christopher; Dickson, Rolland.

In: Liver Transplantation, Vol. 10, No. 5, 05.2004, p. 599-606.

Research output: Contribution to journalArticle

Machicao, Victor I. ; Krishna, Murli ; Bonatti, Hugo ; Aqel, Bashar A. ; Nguyen, Justin H ; Weigand, Stephen D. ; Rosser, Barry G. ; Hughes, Christopher ; Dickson, Rolland. / Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation. In: Liver Transplantation. 2004 ; Vol. 10, No. 5. pp. 599-606.
@article{db199e82c4154b3888aad7886c69e74d,
title = "Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation",
abstract = "The natural history of allograft steatosis in hepatitis C (HCV)-infected patients after liver transplantation (LT) is poorly understood. The aim of our study was to determine the relationship of allograft steatosis to HCV recurrence after LT. All patients undergoing LT at our center from March 1998 to December 2001 were included in the study. Explanted liver tissue and liver biopsies performed at 1 week, 4 months, and 12 months were scored for degree of allograft steatosis (0-4), fibrosis (0-6), and modified histological activity index (0-18). One hundred sixty-seven HCV and 235 non-HCV-infected patients (control group) underwent LT. Of these patients, 122 HCV and 154 non-HCV patients had a viable graft at 1 year and were analyzed. Allograft steatosis was present in 40{\%} of HCV patients at 4 months and 36{\%} at 1 year. The incidence of allograft steatosis after LT was similar in HCV-infected and non-HCV-infected patients (P not significant). Age of the donor (P = .041), or higher recipient body mass index (BMI) at the time of LT (P = .015) or at 12 months after LT (P = .041) predicted a higher degree of allograft steatosis at 12 months in the HCV group. Degree of allograft steatosis was not associated with higher fibrosis or necroinflammatory score. In conclusion, there is a similar high incidence of allograft steatosis in HCV and non-HCV-infected patients after LT. A high BMI of the HCV-infected recipient is the best predictor for high degree of allograft steatosis after LT. Allograft steatosis does not predict the severity of HCV recurrence in the first 12 months after LT.",
author = "Machicao, {Victor I.} and Murli Krishna and Hugo Bonatti and Aqel, {Bashar A.} and Nguyen, {Justin H} and Weigand, {Stephen D.} and Rosser, {Barry G.} and Christopher Hughes and Rolland Dickson",
year = "2004",
month = "5",
doi = "10.1002/lt.20107",
language = "English (US)",
volume = "10",
pages = "599--606",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation

AU - Machicao, Victor I.

AU - Krishna, Murli

AU - Bonatti, Hugo

AU - Aqel, Bashar A.

AU - Nguyen, Justin H

AU - Weigand, Stephen D.

AU - Rosser, Barry G.

AU - Hughes, Christopher

AU - Dickson, Rolland

PY - 2004/5

Y1 - 2004/5

N2 - The natural history of allograft steatosis in hepatitis C (HCV)-infected patients after liver transplantation (LT) is poorly understood. The aim of our study was to determine the relationship of allograft steatosis to HCV recurrence after LT. All patients undergoing LT at our center from March 1998 to December 2001 were included in the study. Explanted liver tissue and liver biopsies performed at 1 week, 4 months, and 12 months were scored for degree of allograft steatosis (0-4), fibrosis (0-6), and modified histological activity index (0-18). One hundred sixty-seven HCV and 235 non-HCV-infected patients (control group) underwent LT. Of these patients, 122 HCV and 154 non-HCV patients had a viable graft at 1 year and were analyzed. Allograft steatosis was present in 40% of HCV patients at 4 months and 36% at 1 year. The incidence of allograft steatosis after LT was similar in HCV-infected and non-HCV-infected patients (P not significant). Age of the donor (P = .041), or higher recipient body mass index (BMI) at the time of LT (P = .015) or at 12 months after LT (P = .041) predicted a higher degree of allograft steatosis at 12 months in the HCV group. Degree of allograft steatosis was not associated with higher fibrosis or necroinflammatory score. In conclusion, there is a similar high incidence of allograft steatosis in HCV and non-HCV-infected patients after LT. A high BMI of the HCV-infected recipient is the best predictor for high degree of allograft steatosis after LT. Allograft steatosis does not predict the severity of HCV recurrence in the first 12 months after LT.

AB - The natural history of allograft steatosis in hepatitis C (HCV)-infected patients after liver transplantation (LT) is poorly understood. The aim of our study was to determine the relationship of allograft steatosis to HCV recurrence after LT. All patients undergoing LT at our center from March 1998 to December 2001 were included in the study. Explanted liver tissue and liver biopsies performed at 1 week, 4 months, and 12 months were scored for degree of allograft steatosis (0-4), fibrosis (0-6), and modified histological activity index (0-18). One hundred sixty-seven HCV and 235 non-HCV-infected patients (control group) underwent LT. Of these patients, 122 HCV and 154 non-HCV patients had a viable graft at 1 year and were analyzed. Allograft steatosis was present in 40% of HCV patients at 4 months and 36% at 1 year. The incidence of allograft steatosis after LT was similar in HCV-infected and non-HCV-infected patients (P not significant). Age of the donor (P = .041), or higher recipient body mass index (BMI) at the time of LT (P = .015) or at 12 months after LT (P = .041) predicted a higher degree of allograft steatosis at 12 months in the HCV group. Degree of allograft steatosis was not associated with higher fibrosis or necroinflammatory score. In conclusion, there is a similar high incidence of allograft steatosis in HCV and non-HCV-infected patients after LT. A high BMI of the HCV-infected recipient is the best predictor for high degree of allograft steatosis after LT. Allograft steatosis does not predict the severity of HCV recurrence in the first 12 months after LT.

UR - http://www.scopus.com/inward/record.url?scp=2442629609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442629609&partnerID=8YFLogxK

U2 - 10.1002/lt.20107

DO - 10.1002/lt.20107

M3 - Article

C2 - 15108251

AN - SCOPUS:2442629609

VL - 10

SP - 599

EP - 606

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 5

ER -